Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings.
Haplo-HSCT is a feasible treatment option for hematological malignancies, yielding satisfactory outcomes with controllable side effects. Enhanced monitoring and early intervention strategies can further improve patient outcomes. Advocating for haplo-HSCT to be accessible for treatment in developing countries could significantly improve patient survival outcomes.
Authors
- Ekapun Karoopongse
- Jane Jianthanakanon
- Pongthep Vittayawacharin (ORCID: https://orcid.org/0000-0002-1131-5564)
- Wichitchai Bintaprasit
- Panpimon Luangtrakool
- Weerapat Owattanapanich (ORCID: https://orcid.org/0000-0002-1262-2005)
- Smith Kungwankiattichai (ORCID: https://orcid.org/0000-0001-6072-4025)
- Chutima Kunacheewa (ORCID: https://orcid.org/0000-0002-3429-5826)
- Janejira Kittivorapart (ORCID: https://orcid.org/0000-0002-4051-8686)
- Suparat Atakulreka
- Sutthisak Chamsai
- Utairat Meeudompong
- Natchanon Sathapanapitagkit
- Nawapotch Donsakul
- Thanatphak Warindpong
- Ratana Bundhit
- Chiraporn Kongsomchit
- Nootjaree Poonmee
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- DOI
- https://doi.org/10.2147/jbm.s511039
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00